28,781 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Acquired by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 28,781 shares of the company's stock, valued at approximately $678,000.

Other large investors have also modified their holdings of the company. abrdn plc acquired a new stake in shares of Dyne Therapeutics in the fourth quarter valued at approximately $608,000. Raymond James Financial Inc. acquired a new stake in shares of Dyne Therapeutics during the fourth quarter worth $2,340,000. Barclays PLC lifted its holdings in shares of Dyne Therapeutics by 162.2% during the third quarter. Barclays PLC now owns 207,309 shares of the company's stock worth $7,446,000 after purchasing an additional 128,246 shares during the period. Schroder Investment Management Group lifted its holdings in shares of Dyne Therapeutics by 63.3% during the fourth quarter. Schroder Investment Management Group now owns 147,002 shares of the company's stock worth $3,477,000 after purchasing an additional 56,961 shares during the period. Finally, Wells Fargo & Company MN lifted its holdings in shares of Dyne Therapeutics by 54.5% during the fourth quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock worth $913,000 after purchasing an additional 13,677 shares during the period. 96.68% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 6,237 shares of company stock worth $77,760 in the last three months. 14.14% of the stock is owned by insiders.

Dyne Therapeutics Trading Up 10.1%

NASDAQ DYN traded up $1.15 during trading on Monday, reaching $12.56. 4,777,508 shares of the company's stock were exchanged, compared to its average volume of 1,659,780. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $47.45. The company's fifty day simple moving average is $10.37 and its 200-day simple moving average is $17.98. The firm has a market capitalization of $1.43 billion, a PE ratio of -3.53 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). Equities analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on DYN shares. Royal Bank of Canada reissued an "outperform" rating and issued a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Chardan Capital restated a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Friday. JPMorgan Chase & Co. decreased their target price on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Scotiabank began coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 target price on the stock. Finally, Guggenheim restated a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Dyne Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $46.85.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.